GR3034417T3 - Use of dibutyl adipate and isopropyl myristate in topical and transdermal products. - Google Patents

Use of dibutyl adipate and isopropyl myristate in topical and transdermal products.

Info

Publication number
GR3034417T3
GR3034417T3 GR20000402105T GR20000402105T GR3034417T3 GR 3034417 T3 GR3034417 T3 GR 3034417T3 GR 20000402105 T GR20000402105 T GR 20000402105T GR 20000402105 T GR20000402105 T GR 20000402105T GR 3034417 T3 GR3034417 T3 GR 3034417T3
Authority
GR
Greece
Prior art keywords
dibutyl adipate
isopropyl myristate
topical
transdermal products
transdermal
Prior art date
Application number
GR20000402105T
Other languages
Greek (el)
English (en)
Inventor
Prakash V Parab
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of GR3034417T3 publication Critical patent/GR3034417T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
GR20000402105T 1991-05-17 2000-09-18 Use of dibutyl adipate and isopropyl myristate in topical and transdermal products. GR3034417T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70194491A 1991-05-17 1991-05-17
US79093991A 1991-11-12 1991-11-12

Publications (1)

Publication Number Publication Date
GR3034417T3 true GR3034417T3 (en) 2000-12-29

Family

ID=27106880

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000402105T GR3034417T3 (en) 1991-05-17 2000-09-18 Use of dibutyl adipate and isopropyl myristate in topical and transdermal products.

Country Status (13)

Country Link
EP (1) EP0513832B1 (enExample)
JP (1) JP3331414B2 (enExample)
AT (1) ATE194919T1 (enExample)
AU (1) AU660017B2 (enExample)
CA (1) CA2068763C (enExample)
DE (1) DE69231287T2 (enExample)
DK (1) DK0513832T3 (enExample)
ES (1) ES2148158T3 (enExample)
GR (1) GR3034417T3 (enExample)
IE (1) IE921573A1 (enExample)
MX (1) MX9202235A (enExample)
PT (1) PT513832E (enExample)
TW (1) TW218849B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4335933C2 (de) * 1993-10-21 1998-09-03 Stockhausen Chem Fab Gmbh Hautreinigungsmittel
US5420106A (en) * 1994-03-22 1995-05-30 Bristol-Myers Squibb Company Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
JP3576608B2 (ja) 1994-11-15 2004-10-13 日東電工株式会社 貼付剤および貼付製剤
US5702720A (en) * 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
DE19616539A1 (de) * 1996-04-25 1997-11-06 Luitpold Pharma Gmbh Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1572178B1 (en) 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
EP2050443B1 (en) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
CA2519980C (en) 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DE602004013439T2 (de) 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
CA2578999A1 (en) * 2004-09-01 2006-03-16 Trustees Of Boston University Use of thyroid hormone conversion inhibitors
RS52671B (sr) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc Poboljšani gel testosterona i postupak korišćenja
WO2007046315A1 (ja) * 2005-10-17 2007-04-26 Nisshin Kyorin Pharmaceutical Co., Ltd. 皮膚外用剤
WO2009015366A2 (en) * 2007-07-26 2009-01-29 Trustees Of Boston University Use of thyroid hormone conversion inhibitors to treat hyperproliferative disorders
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8962028B2 (en) * 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
HUE050603T2 (hu) * 2015-06-18 2020-12-28 Bausch Health Ireland Ltd Egy kortikoszteroidot és egy retinoidot tartalmazó topikális készítmények psoriasis kezelésére

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU84059A1 (fr) * 1982-03-31 1982-07-08 Glaxo Group Ltd Nouvelles compositions pharmaceutiques comprenant des steroides anti-inflammatoires
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
DE68917292T2 (de) * 1988-02-26 1995-02-02 Riker Laboratories Inc Transdermales estradiol als therapeutisches sytem.
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
JP2593714B2 (ja) * 1989-09-20 1997-03-26 株式会社 林原生物化学研究所 色白剤

Also Published As

Publication number Publication date
DK0513832T3 (da) 2000-09-18
PT513832E (pt) 2000-11-30
CA2068763C (en) 2001-07-31
ES2148158T3 (es) 2000-10-16
JP3331414B2 (ja) 2002-10-07
DE69231287D1 (de) 2000-08-31
CA2068763A1 (en) 1992-11-18
AU660017B2 (en) 1995-06-08
ATE194919T1 (de) 2000-08-15
MX9202235A (es) 1993-05-01
IE921573A1 (en) 1992-11-18
AU1632792A (en) 1992-11-19
EP0513832A1 (en) 1992-11-19
JPH05178764A (ja) 1993-07-20
TW218849B (enExample) 1994-01-11
EP0513832B1 (en) 2000-07-26
DE69231287T2 (de) 2001-03-15

Similar Documents

Publication Publication Date Title
AU1632792A (en) Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB2260079B (en) Pharmaceutical composition containing felbinac
TW221027B (enExample)
TW276254B (enExample)
IL106562A0 (en) Pharmaceutical and/or cosmetic compositions and the use thereof
EP0435436A3 (en) Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
AU4089889A (en) Method of treating skin injuries using thromboxane a2 receptor antagonists
AU4877090A (en) Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substances
AU3459689A (en) Treatment of skin disorders
AU4207893A (en) Use of cosmetic composition
GR900100644A (en) Derma atropho glycocorticoids leversal
FR2687913B1 (enExample)
TR200000270T2 (tr) Vücut bakım malzemeleri için koruyucu sistem.
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
DE69300854D1 (de) Mittel zur topischen Verabreichung von Spironolakton.
EP0249193A3 (en) Vehicle for topical application of pharmaceuticals
AU8132587A (en) Penetration enhancers for transdermal delivery of systemic agents
FI88359C (fi) Foerfarande foer framstaellning av en kardiovaskulaer komposition att anvaendas lokalt

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees